Asset Name: IBI324 (OLN324) Licensor (Seller): Innovent Biologics (China) Licensee (Buyer): Ollin Biosciences (US) . Asset … [Unannounced Deal] Innovent and Ollin entered a License for VEGF/Ang2 Bispecific Antibody IBI324 (OLN324)Read more
[China BD 2025] Mabwell and Kalexo enters License on siRNA Program 2MW7141
Announced Date: 2025-09-17 (September 17, 2025) Asset Name: 2MW7141 Licensor (Seller): Mabwell Bio (China) Licensee (Buyer): … [China BD 2025] Mabwell and Kalexo enters License on siRNA Program 2MW7141Read more
China NMPA Approved New Drugs (Biological Products)
Target Drug Name Code Approved Time Company Partner PD-1 mAb Toripalimab JS001 2018-12 Junshi LO: Coherus … China NMPA Approved New Drugs (Biological Products)Read more
China NMPA Approved New Drugs （Small Molecule）
Target Drug Name RD Code Approved(CN) Company Partner EGFR-TKI (Gen 1) Icotinib 2011-06 Betta EGFR-TKI Fruquintinib … China NMPA Approved New Drugs （Small Molecule）Read more
[China BD 2025] Hengrui and Braveheart Bio (NewCo) enters a 1 billion USD license on Myosin inhibitor HRS-1893
Announced Date: 2025-09-05 (September 5, 2025) Asset Name: HRS-1893 Licensor: Jiangsu Hengrui Pharmaceuticals (China) Licensee (Buyer): … [China BD 2025] Hengrui and Braveheart Bio (NewCo) enters a 1 billion USD license on Myosin inhibitor HRS-1893Read more
[China BD 2025] Argo Biopharma and Novartis enters License and Option on Four siRNA Programs
Announced Date: 2025-09-03 (September 3, 2024) Asset Name: Four siRNA programs Licensor: Shanghai Argo Biopharmaceutical (China) … [China BD 2025] Argo Biopharma and Novartis enters License and Option on Four siRNA ProgramsRead more
[China BD 2025] Novatim and Radiance enters a 1 billion USD license on MET/EGFR BsADC KY-0301
Announced Date: 2025-08-29 (August 29, 2025) Asset Name: KY-0301 Licensor: Novatim (Novatim Immune Therapeutics, China) Licensee … [China BD 2025] Novatim and Radiance enters a 1 billion USD license on MET/EGFR BsADC KY-0301Read more
[China BD Deal] Fosun and Sitala enters a 670 million license on CFBi FXS6837
Announced Date: 2025-08-26 (August 26, 2025) Asset Name: FXS6837 （Other code: XH-S003） Licensor: Fosun Pharma and … [China BD Deal] Fosun and Sitala enters a 670 million license on CFBi FXS6837Read more
[China BD Deal] RemeGen and Santen enters a 1.3 billion RMB license on Anti-VEGF/FGF Fusion Protein RC28-E
Announced Date: 2025-08-19 (August 19, 2025) Asset Name: RC28-E Intravitreal Injection Licensor: RemeGen (RemeGen Co., Ltd., … [China BD Deal] RemeGen and Santen enters a 1.3 billion RMB license on Anti-VEGF/FGF Fusion Protein RC28-ERead more
[China BD Deal] Fosun and Expedition achieved a 645 million license on DPP-1 i XH-S004
Announced Date: 2025-08-11 (August 11, 2025) Asset Name: XH-S004 Licensor: Shanghai Fosun Pharmaceutical (Group) Co., Ltd. … [China BD Deal] Fosun and Expedition achieved a 645 million license on DPP-1 i XH-S004Read more